Rébé Cédric, Ghiringhelli François
Platform of Transfer in Cancer Biology, Centre Georges François Leclerc, INSERM LNC UMR1231, University of Bourgogne Franche-Comté, F-21000 Dijon, France.
Cancers (Basel). 2020 Jul 4;12(7):1791. doi: 10.3390/cancers12071791.
Within a tumor, IL-1β is produced and secreted by various cell types, such as immune cells, fibroblasts, or cancer cells. The IL1B gene is induced after "priming" of the cells and a second signal is required to allow IL-1β maturation by inflammasome-activated caspase-1. IL-1β is then released and leads to transcription of target genes through its ligation with IL-1R1 on target cells. IL-1β expression and maturation are guided by gene polymorphisms and by the cellular context. In cancer, IL-1β has pleiotropic effects on immune cells, angiogenesis, cancer cell proliferation, migration, and metastasis. Moreover, anti-cancer treatments are able to promote IL-1β production by cancer or immune cells, with opposite effects on cancer progression. This raises the question of whether or not to use IL-1β inhibitors in cancer treatment.
在肿瘤内部，白细胞介素-1β（IL-1β）由多种细胞类型产生并分泌，如免疫细胞、成纤维细胞或癌细胞。IL1B基因在细胞“启动”后被诱导，并且需要第二个信号来使炎性小体激活的半胱天冬酶-1促进IL-1β成熟。然后IL-1β被释放，并通过与靶细胞上的IL-1R1结合导致靶基因转录。IL-1β的表达和成熟受基因多态性和细胞环境的引导。在癌症中，IL-1β对免疫细胞、血管生成、癌细胞增殖、迁移和转移具有多效性作用。此外，抗癌治疗能够促进癌细胞或免疫细胞产生IL-1β，对癌症进展具有相反的影响。这就提出了在癌症治疗中是否使用IL-1β抑制剂的问题。
